Sign in
PH

P3 Health Partners Inc. (PIII)·Q2 2025 Earnings Summary

Executive Summary

  • Q2 2025 revenue was $355.8M (-6% YoY), with medical margin of $30.6M ($89 PMPM); excluding prior-period adjustments, medical margin was $39.3M ($114 PMPM) and adjusted EBITDA loss improved to -$8.5M ($-25 PMPM) from reported -$17.1M ($-50 PMPM) .
  • Wall Street consensus: revenue slightly missed ($355.8M vs $359.4M*), and EPS missed (-$6.23 vs -$4.30*); Q1 2025 had a revenue beat ($373.2M vs $362.1M*) but larger loss than EPS consensus (-$6.28 vs -$7.915*) .
  • Management revised FY25 guidance: Adjusted EBITDA to a loss of $(69)–$(39)M (from $(35)–$5M), medical margin to $124–$154M (from $174–$210M), PMPM $90–$111 (from $133–$147); revenue unchanged at $1.35–$1.50B; at-risk members maintained at 109–119k .
  • Strategic catalysts: 75% of payer contract renegotiations completed ($5M Q2 EBITDA uplift, ~$20M 2025 improvements), base-rate and benefit-design tailwinds expected for 2026, and identified $120–$170M incremental EBITDA opportunities positioning for 2026 profitability .

What Went Well and What Went Wrong

What Went Well

  • Per-member funding improved ~10% YoY on a normalized basis; management maintained flat medical cost trends despite sector inflation, reflecting the Care Enablement model’s impact .
  • Q2 operational wins included hospice/palliative care program enhancements driving ~$10M medical expense reduction and a renegotiated payer contract contributing ~$5M EBITDA uplift, with ~75% of priority payer renegotiations completed .
  • Three of four markets were breakeven or better through 1H25; “Our core business continues to strengthen as we execute on our $130 million EBITDA improvement plan,” CEO Aric Coffman said .

What Went Wrong

  • Prior-period adjustments (net ~$9M) negatively affected Q2 results (quality measure shortfall and RAF adjustments), masking normalized improvement; Q1 also had prior-year claims impacts .
  • Membership declined to ~115k (-9% YoY) due to network/payer rationalization; total revenue fell -6% YoY .
  • FY25 guidance was lowered materially (Adjusted EBITDA loss midpoint ~$(54)M vs prior midpoint $(15)M), driven by prior-period headwinds and underperformance with a single payer/market (Oregon) .

Financial Results

MetricQ4 2024Q1 2025Q2 2025
Total Revenue ($USD Millions)$370.686 $373.225 $355.788
YoY Revenue Growth+7% -4% -6%
EPS (Basic, $)$(0.36) $(6.28) $(6.23)
Medical Margin ($USD Millions)$7.278 $17.200 $30.615
Medical Margin PMPM ($)$19 $49 $89
Adjusted EBITDA ($USD Millions)$(67.582) $(22.190) $(17.110)
Adjusted EBITDA PMPM ($)$(175) $(64) $(50)
At-Risk Membership (000s)—115.9 ~115.0

Notes: Q2 normalized (ex-PY items): medical margin $39.3M ($114 PMPM) and adjusted EBITDA loss -$8.5M ($-25 PMPM) .

Consensus vs ActualQ4 2024Q1 2025Q2 2025
Revenue Consensus Mean ($USD)$378.884M*$362.066M*$359.431M*
Revenue Actual ($USD)$370.686M $373.225M $355.788M
Primary EPS Consensus Mean ($)$(5.50)*$(7.915)*$(4.30)*
EPS Actual (Basic, $)$(0.36) $(6.28) $(6.23)

Values with asterisk retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
At-Risk MembersFY 2025109,000–119,000 109,000–119,000 Maintained
Total Revenues ($USD Millions)FY 2025$1,350–$1,500 $1,350–$1,500 Maintained
Medical Margin ($USD Millions)FY 2025$174–$210 $124–$154 Lowered
Medical Margin PMPM ($)FY 2025$133–$147 $90–$111 Lowered
Adjusted EBITDA ($USD Millions)FY 2025$(35)–$5 $(69)–$(39) Lowered

Earnings Call Themes & Trends

TopicQ4 2024 (Prev Q-2)Q1 2025 (Prev Q-1)Q2 2025 (Current)Trend
Contract renegotiations & fundingIdentified $130M+ programmatic opportunities; affirmed FY25 guidance Affirmed guidance; focus on payment integrity, tech investment ~75% renegotiations complete; ~$5M Q2 EBITDA uplift; ~$20M 2025 improvements; reduce Part D exposure Strengthening
Medical cost trendElevated costs; weak margins Care Enablement model ramping; PY claim headwinds Flat medical trend ex-PY; clinical programs (COPD, end-of-life) improving utilization Improving
Membership/networkFY24 at-risk +14% to 123.8k Avg at-risk 115.9k, -8%; rationalization ~115k, -9%; 65% Tier 1 providers Quality-focused stabilization
2026 macro tailwindsPositioning for sustainability Long-term vision reiterated Base-rate increase; benefit-design rationalization; $120–$170M EBITDA opportunities Building
Regional performance——Underperformance concentrated with single payer/market (Oregon); mitigation underway Mixed
Technology/AI enablement——Rolling out AI automation for ED follow-ups and quality alerts; EMR integration across SNFs Expanding
Liquidity/debt——~$39M liquidity; debt amendment/extension near finalization; $40M accordion Proactive

Management Commentary

  • CEO: “Our core business continues to strengthen… With an additional $120 to $170 million in identified EBITDA opportunities and three of our four markets already EBITDA positive or breakeven, P3 is well-positioned to achieve sustained profitability in 2026 and beyond” .
  • CFO: “We are encouraged by the performance of our core business… Though some progress has been masked by prior period dynamics, we are seeing signs of stabilization and traction for future margin recovery” .
  • CMO: “Programs such as hospital at home… improved management of COPD… and palliative and hospice services… reduced admissions and length-of-stay; we’re rolling out AI automation for ED follow-up calls and quality metric alerts to reduce staff documentation time” .
  • CEO on contracts: “We are on track to hit our 2025 goal of at least $20,000,000 in improvements across our remaining priority payer contracts with 75% completed” .

Q&A Highlights

  • Prior-period adjustments: ~$9M net unfavorable in Q2, tied to RAF accrual correction, missed quality measure, and timing/data issues at specific plans; management revamped processes and expects no further impact in 2H25 .
  • Market concentration: Underperformance is concentrated with a single payer/market; management has reduced exposure and expects structural fixes to benefit 2026; will take further steps if needed .
  • 2026 outlook confidence: Base-rate increases, benefit-design changes (less PPO), accurate burden-of-illness capture, operational levers, and contractual enhancements comprise the $120–$170M EBITDA opportunity set .
  • Data/contract terms: Management is working to tighten data exchange cadence and pursue protective clauses; some delegation gives P3 more direct data control .
  • Cost controls: Workforce down ~25% since Jan 2024; operating expense reduction highlighted alongside reinvestment in field operations and quality .

Estimates Context

  • Q2 2025: Revenue slightly missed ($355.8M actual vs $359.4M* consensus) and EPS missed (-$6.23 actual vs -$4.30* consensus) .
  • Q1 2025: Revenue beat ($373.2M actual vs $362.1M*) but EPS was worse than consensus (-$6.28 vs -$7.915*) .
  • Q4 2024: Revenue missed ($370.7M actual vs $378.9M*); EPS comparability complicated by post-April 2025 reverse split—documented actual was -$0.36 basic (pre-split reporting in press release) .
    Values with asterisk retrieved from S&P Global. Guidance reductions imply consensus estimates for FY25 medical margin and EBITDA will need to be revised lower.

Key Takeaways for Investors

  • Near-term: Q2 normalized metrics improved (ex-PY items), but reported misses and guidance cuts are likely to pressure estimates and sentiment; watch resolution of the outlier payer/market and evidence of 2H momentum .
  • Contracting: ~75% completed renegotiations plus further Part D risk mitigation and quality-linked triggers support funding and margin tailwinds; monitor additional payouts and contract amendments in 2H25 .
  • Clinical programs: Hospice/palliative and COPD initiatives materially reducing medical expense; scaling AI-enabled workflows and SNF EMR integration should sustain utilization improvements into 2026 .
  • Liquidity/capital structure: ~$39M liquidity and anticipated debt amendment/extension and accordion access reduce financing risk, but execution on cost and margin recovery remains critical .
  • 2026 setup: Identified $120–$170M EBITDA opportunities across macro rate/design changes, operations, and contracting create a credible path to profitability if execution holds .
  • KPIs to track: Medical margin PMPM, adjusted OpEx, prior-period adjustment run-rate, at-risk membership mix/tiering, and payer exposure concentration .
  • Legal/PR backdrop: Multiple law-firm investigations noted in period press flow—monitor for developments, though core operational narrative remains the principal stock driver .

Additional Relevant Press Releases (Q2 2025 timeframe)

  • Scheduling release for Q2 earnings call (Aug 14, 2025) .
  • Catalyst Solutions announced successful launch supporting P3 across configurations, claims, and provider call center for eleven health plans (~68k members) across four states (go-live May 2025; release Aug 25) .